subdermal GLP-1 implants for the treatment of chronic weight management in obese or overweight human patients and type 2 diabetes, respectively,” Mendelsohn added. Vivani has separately ...

NPM-119 refers to the Company’s six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients ...

NPM-119 refers to the Company’s six-month, subdermal, GLP-1 (exenatide) implant under development for the treatment of type 2 diabetes. These NanoPortal implants are designed to provide patients ...

Portfolio of miniature, once or twice-yearly GLP-1 implants in development for chronic weight management and type 2 diabetes Vivani CEO Adam ...

Try it free for 7 days Vivani Medical, Inc. VANI, on Wednesday, released preclinical data for NPM-139, its subdermal ... than a sham implant control group throughout a 91-day treatment period.

Vivani Medical, Inc. (NASDAQ:VANI) and Okava Pharmaceuticals, Inc. expanded their collaboration to include dogs in the development of OKV-119, a long-acting GLP-1 therapy for weight management, ...

The use of drugs like Ozempic, Wegovy and Zepbound in people with type 1 diabetes has risen sharply over the past decade, a new study finds, even though there’s little information on the drugs ...

NPM-139 treatment resulted in nearly 20% placebo-adjusted weight loss from a single administration with expected once or twice-yearly dosing NPM-139 is a miniature, subdermal implant in ...